中国防痨杂志2025，Vol.47Issue(11)：1391-1415,25.DOI:10.19982/j.issn.1000-6621.20250254
结核病共病治疗中利福霉素类药物合理应用专家共识
Expert consensus on the rational use of rifamycins in the treatment of tuberculosis with comorbidities
摘要
Abstract
Tuberculosis frequently coexists with multiple chronic diseases,necessitating combination pharmacotherapy.Rifamycin-class anti-tuberculosis agents exhibit clinically significant interactions with many drugs used to treat comorbidities,potentially reducing their efficacy,causing treatment failure,or increasing toxicity.However,evidence-based clinical guidance on these interactions is currently lacking.To improve clinicians' understanding of the interactions between rifamycins and medications for comorbid conditions and to support their rational use,this consensus statement was developed.It was based on a systematic review of domestic and international literature,drug-label information,and appraisal of the best available evidence,and was finalized after three rounds of focused discussion and revision.The document covers an overview of rifamycins agents,their mechanisms of drug-drug interaction,guiding principles for clinical application,and a comprehensive summary of evidence on interactions with commonly prescribed comorbidity medications,together with practical dose-adjustment recommendations.The aim is to provide safe and effective rifamycin-based therapeutic regimens for tuberculosis patients with comorbidities and to offer an actionable reference for clinical practice.关键词
利福霉素类/结核/共病现象/治疗应用/指南Key words
Rifamycins/Tuberculosis/Comorbidity/Therapeutic uses/Guidebooks分类
医药卫生引用本文复制引用
深圳市第三人民医院(国家感染性疾病临床医学研究中心),中国防痨协会结核病与糖尿病专业分会,中国防痨协会多学科诊疗专业分会,邓国防,徐勇,刘妙娜,路希维..结核病共病治疗中利福霉素类药物合理应用专家共识[J].中国防痨杂志,2025,47(11):1391-1415,25.基金项目
Guangzhou National Laboratory Project(GZNL2024A01030) （GZNL2024A01030）
Guangdong Clinical Research Center for Infectious Diseases(Tuberculosis)(2020B1111170014) （Tuberculosis）
Shenzhen Clinical Research Center for Tuberculosis(20210617141509001) （20210617141509001）
Shenzhen Medical Research Foundation(C2401026) 广州国家实验室项目(GZNL2024A01030) （C2401026）
广东省感染性疾病(结核病)临床医学研究中心(2020B1111170014) （结核病）
深圳市结核病临床医学研究中心(20210617141509001) （20210617141509001）
深圳市医学研究专项资金(C2401026) （C2401026）
